Search results
Showing 61 to 75 of 166 results for atrial fibrillation
Recommendation ID NG106/3 Question The impact of atrial fibrillation on the natriuretic peptide threshold for diagnosing heart failure:-...
people with atrial fibrillation: Which automated blood pressure monitors are suitable for people with hypertension and atrial...
ID NG196/2 Question Tests to diagnose paroxysmal atrial fibrillation: What is the diagnostic accuracy of key index tests compared with
Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias (MIB276)
NICE has developed a medtech innovation briefing (MIB) on Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias .
ID NG196/1 Question Tests to diagnose persistent atrial fibrillation: What is the diagnostic accuracy of key index tests (such as the...
and cost effectiveness of stopping anticoagulation in people whose atrial fibrillation has resolved after ablation? Any explanatory...
Rate-control drug treatment for people aged 75 and over with atrial fibrillation: What is the comparative effectiveness of the 3 main...
balloon cryoablation in relation to other procedures for treating atrial fibrillation. Further research should define patient selection...
from UK primary care databases clarify stroke risk in people with atrial fibrillation according to baseline risk factors and treatment?...
This indicator covers the percentage of patients with heart failure diagnosed within the preceding 15 months with a record of an offer of referral for an exercise-based rehabilitation programme. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM48
Stroke and ischaemic attack: anti-platelet or anticoagulation (IND133)
This indicator covers the percentage of patients with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record in the preceding 12 months that an anti-platelet agent, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM94.
Find out more about the progress made in implementing NICE guidance on cardiovascular disease prevention
Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.
Irreversible electroporation for treating liver metastases (IPG445)
Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.
View recommendations for IPG445Show all sections
Sections for IPG445